# Gene Therapy Research Partnerships

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Science Officer
**Purpose**: Define strategy for partnering with gene therapy companies, supporting clinical trials, and preparing AATD community for curative treatmentsâ€”positioning Foundation as bridge between research and patients

---

## ğŸ“‹ Table of Contents

1. [Gene Therapy Overview](#gene-therapy-overview)
2. [Current Landscape](#current-landscape)
3. [Foundation's Role](#foundations-role)
4. [Partnership Strategy](#partnership-strategy)
5. [Clinical Trial Support](#clinical-trial-support)
6. [Patient Education & Preparation](#patient-education--preparation)
7. [Regulatory Advocacy](#regulatory-advocacy)
8. [Long-Term Vision](#long-term-vision)
9. [Timeline & Investment](#timeline--investment)
10. [Success Metrics](#success-metrics)

---

## Gene Therapy Overview

### The Promise: One-Time Cure for AATD

**Current Treatment Reality**:

- Augmentation therapy: Weekly IV infusions for life ($100K-$200K/yearâ€”never cured, only managed)
- Lung transplant: Last resort (5-year survival 50-60%â€”not curative, immunosuppression forever)
- Liver transplant: For liver disease (cures AATDâ€”but major surgery, donor shortage, lifelong drugs)

**Gene Therapy Vision**:

- One-time treatment (single infusion or injection)
- Permanent cure (corrected genes produce normal AATâ€”for life)
- No more infusions (patient independenceâ€”free from weekly therapy)
- Prevents progression (start earlyâ€”protect lungs before damage occurs)

**What Is Gene Therapy?**

- **Gene Addition**: Insert healthy M gene into liver cells (cells produce normal AATâ€”supplements deficient production)
- **Gene Editing**: Fix Z mutation â†’ M mutation (CRISPR, base editorsâ€”correct defect at DNA level)
- **Gene Silencing + Replacement**: Turn off Z gene (stop producing toxic protein) + add M gene (restore normal AAT)

---

### Why Gene Therapy for AATD Makes Sense

**AATD is "Ideal" Gene Therapy Target**:

- âœ… **Single gene defect** (SERPINA1 geneâ€”one target to fix)
- âœ… **Well-understood biology** (50+ years researchâ€”know exactly what's broken, how to fix)
- âœ… **Liver target** (AAT produced in liverâ€”accessible organ, proven target for gene therapy)
- âœ… **Protein secreted** (once liver cells corrected, AAT circulates to lungsâ€”no need to edit lung cells directly)
- âœ… **Small correction needed** (10-15% of normal production may be therapeuticâ€”don't need 100% efficiency)
- âœ… **Existing biomarker** (plasma AAT levelâ€”easy to measure success)

**Precedent**:

- Hemophilia gene therapy (approved 2022â€”similar biology, liver-targeted AAV therapy, one-time cure)
- Sickle cell gene therapy (approved 2023â€”CRISPR editing, curative)
- $2M-$3M price tag (one-time cost vs. $100K-$200K/year lifetimeâ€”cost-effective over 10-20 years)

---

## Current Landscape

### Gene Therapy Approaches in Development

**1. AAV Gene Addition** (Adeno-Associated Virusâ€”Insert M Gene)

**Companies/Programs**:

- **Applied Genetic Technologies (AGTC)** / **Alcon** (now Asclepix Therapeuticsâ€”after merger)
  - Program: rAAV-AAT (AAV8 vector, liver-targeted, delivers M gene)
  - Status: Phase 1/2 clinical trial (2022-2024â€”dose escalation, safety, efficacy)
  - Results: Plasma AAT increased 30-70 mg/dL (dose-dependentâ€”some patients reached protective levels >50 mg/dL)
  - Duration: Unclear (gene expression may fade over 5-10 yearsâ€”repeat dosing needed?)

- **Moderna Therapeutics**
  - Program: mRNA-AAT (lipid nanoparticle delivery, liver uptake, cells produce AAT from mRNA)
  - Status: Preclinical (animal studiesâ€”moving toward Phase 1)
  - Advantage: Repeat dosing possible (mRNA temporaryâ€”not permanent gene change, but can redose monthly/quarterly if needed)
  - Challenge: Durability (mRNA degradesâ€”need frequent dosing, may not be "cure")

---

**2. CRISPR Gene Editing** (Fix Z â†’ M Mutation)

**Companies/Programs**:

- **Beam Therapeutics**
  - Program: BEAM-302 (base editorâ€”changes single DNA letter, Z â†’ M)
  - Status: Preclinical (IND-enabling studiesâ€”preparing for Phase 1/2 in 2025-2026)
  - Advantage: Permanent correction (edits DNAâ€”no more Z protein produced, M protein replaces it)
  - Challenge: Off-target editing (CRISPR may cut wrong spotsâ€”safety monitoring critical)

- **Intellia Therapeutics** / **Regeneron**
  - Program: In vivo CRISPR (LNP delivery, liver-targeted, CRISPR-Cas9 editing)
  - Status: Preclinical research (AATD not primary focusâ€”working on ATTR amyloidosis, but technology applicable)

---

**3. Gene Silencing + Replacement** (Stop Z, Add M)

**Approach**:

- Use RNAi or antisense oligonucleotide (ASO) to silence Z gene (stop making toxic protein)
- Plus AAV or mRNA to add M gene (restore normal AAT production)
- Advantage: Treats both lung AND liver disease (silencing removes liver toxicity, replacement protects lungs)

**Status**: Academic research (not yet in clinical trialsâ€”proof-of-concept in mice)

---

### Clinical Trial Status (2025)

**Active Trials**:

- AGTC/Asclepix rAAV-AAT: Phase 1/2 (enrollment complete, data analysisâ€”results expected 2025-2026)
- Beam Therapeutics BEAM-302: IND filing 2025 (Phase 1/2 start 2026)

**Near-Term Trials** (Next 2-3 Years):

- Moderna mRNA-AAT: Phase 1 expected 2026-2027
- Additional programs (Intellia, other biotechâ€”interest in AATD growing)

**Timeline to Approval**:

- Optimistic: 2030-2032 (if Phase 1/2 successful, accelerated approvalâ€”like hemophilia gene therapy)
- Realistic: 2032-2035 (Phase 3 trials needed, long-term safety dataâ€”FDA cautious with gene therapy)
- Pessimistic: 2035+ (if durability issues, need repeat dosingâ€”may not qualify as "cure")

---

## Foundation's Role

### Why Foundation Involvement Matters

**Challenge**: Gene therapy companies focus on science, not patients

- Companies: Discover therapy, run trials, get FDA approval (business model: sell to pharma or commercialize)
- Gap: Patient enrollment, education, long-term monitoring, access/affordability (companies less equipped for this)

**Foundation Fills Gaps**:

- âœ… **Patient Recruitment**: Foundation's registry (10,000 patients by Year 5â€”trial-ready population)
- âœ… **Education**: Prepare community (what is gene therapy? risks/benefits? how to participate?)
- âœ… **Trial Support**: Navigate process (screening, consent, travel, follow-upâ€”reduce patient burden)
- âœ… **Advocacy**: Push for access (insurance coverage, pricing negotiationsâ€”ensure patients can afford it)
- âœ… **Long-Term Monitoring**: Post-approval surveillance (5, 10, 20 yearsâ€”track durability, safety)

**Value to Companies**:

- Faster enrollment (registry accelerates patient identificationâ€”trials finish sooner)
- Higher retention (Foundation support reduces dropoutâ€”complete data sets)
- Real-world evidence (Foundation registry tracks outcomesâ€”complement clinical trial data)
- Market access (Foundation advocates for reimbursementâ€”ensure commercial success)

---

## Partnership Strategy

### Tier 1: Clinical Trial Partnerships (Near-Termâ€”2025-2030)

**Target Companies**: AGTC/Asclepix, Beam Therapeutics, Moderna (active programsâ€”trials underway or imminent)

**Foundation Offers**:

1. **Patient Recruitment**:
   - Foundation registry (identify trial-eligible patientsâ€”email, call, educate)
   - Target: 50-100 referrals per trial (accelerate enrollment by 6-12 months)

2. **Trial Site Support**:
   - Co-locate trial visits with Foundation events (annual conference, support groupsâ€”reduce travel burden)
   - Patient navigators (help with logisticsâ€”appointment scheduling, insurance authorization, travel arrangements)

3. **Education & Awareness**:
   - Webinars (introduce trial to communityâ€”explain eligibility, risks/benefits, enrollment process)
   - Materials (FAQs, videos, testimonialsâ€”demystify gene therapy, build trust)

4. **Data Contribution**:
   - Registry data (natural historyâ€”compare trial participants to untreated patients, contextualize outcomes)
   - Biospecimens (blood, DNA, lung functionâ€”pre-trial baseline data)

**Foundation Receives**:

- Trial updates (regular briefingsâ€”share results with community)
- Publication co-authorship (Foundation recognized as collaboratorâ€”scientific credibility)
- Patient access (Foundation patients prioritized for trialsâ€”community benefit)

**Budget**: $500K-$1M per trial partnership (staff time, patient support, education materials)

---

### Tier 2: Research Collaboration (Mid-Termâ€”2025-2032)

**Target**: All gene therapy companies + academic researchers (broader than just active trials)

**Foundation Sponsors Research**:

1. **Durability Studies** ($500K-$1M):
   - Question: How long does AAV gene therapy last? (5 years? 10? 20?)
   - Approach: Long-term follow-up (measure AAT levels annually in trial participantsâ€”track gene expression over time)
   - Value: Informs re-dosing strategy (if expression fades, when to retreat? Foundation helps design long-term monitoring)

2. **Combination Therapy Research** ($500K-$2M):
   - Question: Can gene therapy + protein clearance be synergistic? (e.g., AAV-AAT + carbamazepine to clear existing ZZ polymers)
   - Approach: Animal studies â†’ pilot human trial (Foundation funds, company provides gene therapy)
   - Value: Treat both lung AND liver disease (gene therapy alone may not clear liver polymersâ€”combination could be superior)

3. **Pediatric Feasibility Studies** ($1M-$2M):
   - Question: Can we treat children before lung damage occurs? (gene therapy at age 10-15â€”prevent emphysema entirely?)
   - Approach: Pediatric PK/safety study (enroll 10-20 adolescent AATD patientsâ€”test safety, dosing in younger population)
   - Value: Prevention paradigm (treat before diseaseâ€”not just slow progression, but prevent onset)

**Foundation Receives**:

- IP rights (co-own discoveriesâ€”royalty share if commercialized)
- Scientific advisory board seat (input on trial design, patient selectionâ€”ensure patient-centric approach)

**Budget**: $2M-$5M over 5 years

---

### Tier 3: Access & Affordability Advocacy (Post-Approvalâ€”2030+)

**Once Gene Therapy Approved**:

**Challenge**: $2M-$3M price tag (insurance may not coverâ€”patients can't afford, therapy fails despite FDA approval)

**Foundation Advocates**:

1. **Insurance Coverage**:
   - Meet with payers (Aetna, UnitedHealthcare, Medicareâ€”present cost-effectiveness data)
   - Argument: $2M one-time vs. $100K/year Ã— 30 years = $3M lifetime (gene therapy cost-neutral or savings)
   - Outcome: Coverage policies (insurers agree to cover gene therapyâ€”patients can access)

2. **Pricing Negotiations**:
   - Work with companies (propose outcomes-based contractsâ€”pay only if therapy works)
   - Example: Pay $500K upfront, then $1.5M if AAT levels sustained 5 years (reduce upfront risk for payers)

3. **Patient Assistance**:
   - Foundation fund (financial assistance for uninsured/underinsuredâ€”$500K-$2M/year)
   - Co-pay support (cover patient out-of-pocketâ€”$5K-$50K per patient, ensure no one priced out)

4. **Policy Advocacy**:
   - Lobby CMS (Medicare/Medicaid coverageâ€”set precedent for private insurers)
   - Congress (legislation to support high-cost curative therapiesâ€”loan programs, tax credits for gene therapy)

**Budget**: $5M-$10M over 5 years (post-approval phase)

---

## Clinical Trial Support

### Patient Navigator Program for Gene Therapy Trials

**Service**: Dedicated navigators help patients through trial process (screening â†’ enrollment â†’ treatment â†’ follow-up)

**Components**:

**1. Pre-Screening Education** (Before Enrollment):

- Webinars (what is gene therapy? how does trial work? risks/benefits?)
- 1-on-1 calls (answer questionsâ€”"Am I eligible?" "What if it doesn't work?" "Will I still need augmentation?")
- Decision aids (comparison chartsâ€”gene therapy vs. augmentation, transplantâ€”help patients decide if trial right for them)

**2. Enrollment Support**:

- Eligibility screening (coordinate with trial sitesâ€”check inclusion/exclusion criteria before patient travels)
- Insurance authorization (work with trial coordinatorâ€”ensure visits covered by trial sponsor, not patient)
- Travel assistance (book flights, hotelsâ€”Foundation reimburses up to $2,000 per patient for trial-related travel)

**3. During-Trial Support**:

- Check-ins (monthly callsâ€”"How are you feeling?" "Any side effects?" "Need anything?")
- Peer support (connect with other trial participantsâ€”online forum, phone buddies)
- Logistics help (appointment reminders, lab results trackingâ€”reduce patient burden)

**4. Post-Trial Follow-Up**:

- Long-term monitoring (annual surveysâ€”track AAT levels, lung function, quality of life for years after trial)
- Registry enrollment (integrate trial participants into Foundation registryâ€”build long-term dataset)

**Staffing**:

- 2 Patient Navigators (RN or social workerâ€”experienced with clinical trials, genetics, AATD)
- Serve 50-100 trial participants (across multiple trialsâ€”AGTC, Beam, Moderna, others)

**Budget**: $300K/year (staff, travel reimbursements, materials)

---

### Biospecimen & Data Contribution

**Foundation Collects Pre-Trial Baseline**:

- Blood samples (DNA, plasmaâ€”baseline AAT levels, genotype, biomarkers)
- Lung function (spirometry, CT scanâ€”baseline emphysema severity)
- Quality of life (SF-36, SGRQâ€”baseline symptoms, activity limitation)

**Value to Trials**:

- Historical control data (compare trial participants to registry patientsâ€”strengthen results even without randomized control)
- Subgroup analysis (predict who responds bestâ€”age, baseline AAT, lung functionâ€”personalize therapy)

**Foundation Receives**:

- Trial data (de-identified resultsâ€”add to registry, improve understanding of disease)
- Early access (Foundation patients get priority enrollmentâ€”community benefit)

**Budget**: $200K/year (lab costs, data management)

---

## Patient Education & Preparation

### Challenge: Gene Therapy is New, Complex, Scary

**Patient Concerns**:

- "Will it work?" (gene therapy failed in pastâ€”1999 Jesse Gelsinger death, trust shaken)
- "Is it safe?" (permanent DNA changeâ€”what if something goes wrong?)
- "Will I still need augmentation?" (gene therapy may not fully restore AATâ€”unclear if replacement therapy obsolete)
- "Can I afford it?" ($2M-$3Mâ€”even with insurance, co-pays could be $100K+)
- "What if it wears off?" (durability unknownâ€”might need re-treatment in 5-10 years)

**Foundation's Role**: Build trust, manage expectations, prepare community

---

### Education Program: "Gene Therapy 101"

**1. Webinar Series** (6 webinars over 1 year):

- **Session 1**: "What Is Gene Therapy?" (basicsâ€”how it works, types, history)
- **Session 2**: "Gene Therapy for AATD" (current trials, results so far, timeline to approval)
- **Session 3**: "Risks & Benefits" (safety concerns, realistic expectationsâ€”balance hope with caution)
- **Session 4**: "Clinical Trials 101" (how trials work, eligibility, enrollment process)
- **Session 5**: "Life After Gene Therapy" (post-treatment monitoring, will I still need augmentation?, long-term unknowns)
- **Session 6**: "Cost & Access" (pricing, insurance, financial assistanceâ€”how to prepare)

**Audience**: 500-1,000 patients per webinar (live + recordedâ€”YouTube for later viewing)

**Faculty**: Gene therapy researchers (academic + industryâ€”credible speakers), patient advocates (trial participantsâ€”real experiences)

**Budget**: $50K/year (speaker fees, production, promotion)

---

**2. Patient Stories** (Testimonials from Trial Participants):

- Video interviews (5-10 minâ€”"Why I joined gene therapy trial," "What treatment was like," "How I feel now")
- Written stories (blog postsâ€”750 words, patient perspective)
- Peer support (trial participants available for 1-on-1 callsâ€”answer questions from patients considering trials)

**Impact**: Build trust (real patients, not corporate marketingâ€”relatable, authentic)

**Budget**: $30K/year (video production, patient travel reimbursement for filming)

---

**3. FAQ Document + Decision Aid**:

- Comprehensive FAQ (50+ questionsâ€”addressing all concerns)
- Decision aid (comparison tableâ€”gene therapy vs. augmentation vs. wait-and-see)
- Distribute (website, patient mailings, support groupsâ€”ensure all patients have info)

**Budget**: $20K (content development, design, printing)

---

### Managing Expectations: Gene Therapy â‰  Magic Bullet

**Realistic Messaging**:

- âœ… "Gene therapy MAY cure AATD for some patients" (not guaranteedâ€”response varies)
- âœ… "Early results promising" (30-70 mg/dL AAT increaseâ€”many patients reached protective levels)
- âœ… "Durability unknown" (may last 5-10 years, possibly lifetimeâ€”need long-term data)
- âœ… "Not for everyone" (eligibility criteriaâ€”age, liver function, disease severityâ€”some patients excluded)
- âœ… "Augmentation may still be needed" (gene therapy might not fully restore AATâ€”combination therapy possible)

**Avoid Over-Hyping**:

- âŒ "Gene therapy will cure AATD" (too definitiveâ€”set up for disappointment)
- âŒ "One-time treatment, done forever" (durability unclearâ€”may need re-dosing)
- âŒ "Everyone should wait for gene therapy" (trials take yearsâ€”patients may progress while waiting, augmentation still gold standard for now)

---

## Regulatory Advocacy

### Foundation as Patient Voice to FDA

**FDA Engagement**:

1. **Patient-Focused Drug Development (PFDD) Meeting**:
   - Request FDA host PFDD for AATD (like CF, Duchenneâ€”bring patient perspective into regulatory review)
   - Foundation organizes (recruit patients to testifyâ€”share disease burden, unmet needs, willingness to accept risk)
   - Outcome: FDA hears directly from patients (may influence approval decisionsâ€”faster review, conditional approval, broader label)

2. **Advisory Committee Testimony**:
   - When gene therapy comes to FDA (CBERâ€”Center for Biologics Evaluation & Research, advisory committee review)
   - Foundation testifies (present patient perspectiveâ€”demand for cure, acceptable risk, post-market surveillance plan)
   - Impact: Advisory committee recommendation (approve? additional studies?â€”patient voice matters)

3. **Accelerated Approval Advocacy**:
   - Push for surrogate endpoint approval (AAT level increaseâ€”faster than waiting for lung function decline over 2-3 years)
   - Argument: Life-threatening disease, no cure, unmet need (criteria for accelerated approval met)
   - Outcome: Approval 2-3 years faster (conditional approval based on AAT increase, with post-market lung function study)

**Budget**: $100K/year (FDA meeting travel, consultant fees for regulatory strategy)

---

### CMS Coverage Advocacy (Medicare/Medicaid)

**Post-Approval Challenge**: FDA approval â‰  coverage (CMS may refuse to pay $2M-$3M for gene therapy)

**Foundation Strategy**:

1. **Cost-Effectiveness Analysis**:
   - Commission health economics study ($200Kâ€”academic researchers, model gene therapy vs. augmentation lifetime costs)
   - Result: Gene therapy cost-effective (ICER <$150K/QALYâ€”threshold for "cost-effective" in US)
   - Submit to CMS (National Coverage Determination requestâ€”argue gene therapy should be covered)

2. **Patient Testimonials**:
   - Bring patients to CMS (testify at public comment periodsâ€”personal stories of augmentation burden, need for cure)

3. **Political Pressure**:
   - Work with Congress (patient advocacy dayâ€”meet with legislators, ask for support)
   - Media campaign (op-eds, news storiesâ€”"Medicare Denies Life-Saving Gene Therapy" headlines put pressure on CMS)

**Timeline**: 1-2 years post-FDA approval (CMS review process slowâ€”Foundation accelerates)

**Budget**: $500K over 2 years

---

## Long-Term Vision

### 2030-2035: Gene Therapy Becomes Standard of Care

**Scenario**: Gene therapy approved, covered by insurance, widely available

**Patient Journey** (2035):

- **Age 25**: Diagnosed with AATD (genetic test confirms ZZ)
- **Age 26**: Start augmentation therapy (temporaryâ€”bridge to gene therapy)
- **Age 28**: Eligible for gene therapy (lung function still goodâ€”FEV1 >70%, no significant emphysema)
- **Age 28**: Receive gene therapy (single infusion, outpatient procedure)
- **Age 29**: Stop augmentation (AAT levels >80 mg/dLâ€”protective, therapy no longer needed)
- **Age 30-70+**: Live normal life (no infusions, no restrictionsâ€”cured)

**Foundation's Role** (Post-Approval):

- Patient registry (track 5,000-10,000 gene therapy recipientsâ€”long-term safety, durability, outcomes)
- Re-treatment program (if gene expression fadesâ€”identify patients, facilitate second dose)
- Pediatric expansion (advocate for treating children age 10-15â€”prevent disease before onset)
- Global access (export model to Europe, Asiaâ€”help international AATD communities establish gene therapy access)

---

### 2035-2040: CRISPR Editing Becomes Preferred Approach

**Second-Generation Gene Therapy**:

- Permanent correction (CRISPR base editingâ€”no viral vector, no fading gene expression)
- Treat liver disease too (edit ZZ â†’ M in existing liver cellsâ€”clear toxic polymers, restore normal AAT)
- Lower cost (no ongoing manufacturingâ€”simple editing system, scalable)

**Foundation Advocacy**:

- Fund CRISPR research (preclinical â†’ early clinical trialsâ€”$5M-$10M over 5 years)
- Regulatory strategy (work with FDA on editing safetyâ€”off-target monitoring, long-term surveillance)
- Public education (address CRISPR concernsâ€”"designer babies," ethicsâ€”separate therapeutic editing from germline, build trust)

---

### 2040+: AATD Becomes Preventable Disease

**Newborn Screening + Gene Therapy**:

- All babies screened for AATD at birth (add SERPINA1 to newborn genetic panelâ€”identify ZZ babies)
- Treat at age 5-10 (before any lung damageâ€”gene therapy administered pre-symptomatically)
- Result: Zero AATD patients develop emphysema (disease prevented, not just managed)

**Foundation's Legacy**: Eliminate AATD as cause of lung disease (join polio, smallpoxâ€”diseases relegated to history)

---

## Timeline & Investment

### Years 1-5 (2025-2030): Clinical Trial Support

**Activities**:

- Partner with 2-3 gene therapy companies (AGTC, Beam, Moderna)
- Enroll 100-200 patients in trials (via registry recruitment)
- Education program (webinars, materials, patient stories)
- Regulatory advocacy (FDA PFDD meeting, advisory committee testimony)

**Budget**: $5M ($1M/year)

---

### Years 5-10 (2030-2035): Post-Approval Access & Monitoring

**Activities**:

- Insurance advocacy (CMS coverage, private payer negotiations)
- Patient assistance fund ($500K-$2M/yearâ€”co-pay support)
- Long-term registry (track 5,000 gene therapy recipientsâ€”durability, safety, outcomes)
- Pediatric trial support (advocate for age expansionâ€”treat children/adolescents)

**Budget**: $15M ($1.5M/year for advocacy + $10M for financial assistance)

---

### Years 10-20 (2035-2045): Next-Generation Therapies

**Activities**:

- CRISPR research funding ($5M-$10Mâ€”support academic/industry editing trials)
- Newborn screening advocacy (add AATD to state panelsâ€”early identification)
- Global expansion (export gene therapy model to Europe, Asia, Latin Americaâ€”worldwide AATD cure)

**Budget**: $20M ($1M/year for operations + $10M for CRISPR research)

---

## Success Metrics

### Years 1-5: Clinical Trial Metrics

**Enrollment**:

- 100-200 patients enrolled in gene therapy trials (via Foundation recruitment)
- 50% reduction in trial enrollment time (companies report faster accrualâ€”Foundation registry value demonstrated)

**Education**:

- 5,000 patients educated (attend webinars, read materialsâ€”understand gene therapy)
- 80% awareness (patient surveyâ€”80% of Foundation community aware of gene therapy trials)

**Advocacy**:

- FDA PFDD meeting held (patient voices heardâ€”influence regulatory strategy)

---

### Years 5-10: Access Metrics

**Coverage**:

- Medicare/Medicaid cover gene therapy (CMS National Coverage Determinationâ€”policy in place)
- 90% private insurers cover (policy trackingâ€”most major payers have coverage policies)

**Patient Assistance**:

- 200-500 patients receive financial assistance (Foundation fundâ€”bridge co-pay gaps)
- Zero patients denied therapy due to cost (Foundation safety netâ€”ensures access for all)

**Registry**:

- 5,000 gene therapy recipients tracked (long-term monitoringâ€”build world's largest gene therapy database)

---

### Years 10-20: Transformation Metrics

**Standard of Care**:

- 50-70% of newly diagnosed AATD patients receive gene therapy (vs. augmentationâ€”paradigm shift)
- 80% of gene therapy recipients off augmentation (durable AAT levelsâ€”therapy no longer needed)

**Prevention**:

- Pediatric trials initiated (age 10-15â€”prevent disease before onset)
- AATD added to newborn screening (10+ statesâ€”early identification, early treatment)

**Global Impact**:

- 10,000+ gene therapy recipients worldwide (Foundation model exportedâ€”Europe, Asia adopt similar strategies)

---

## Summary

**Gene Therapy = Potential Cure, Foundation = Bridge to Get There**:

- âœ… **Clinical Trial Support**: Recruit patients, navigate trials, reduce barriers (faster enrollment, higher completion)
- âœ… **Education**: Prepare community (build trust, manage expectationsâ€”informed patients make better decisions)
- âœ… **Advocacy**: Push for access (insurance coverage, pricing negotiationsâ€”ensure patients can afford cure)
- âœ… **Long-Term Monitoring**: Track outcomes (durability, safetyâ€”inform future therapies, support regulatory approvals)

**10-Year Vision**: Gene therapy approved, covered, accessible â†’ thousands cured â†’ AATD no longer lifelong disease

**20-Year Vision**: CRISPR editing perfected, pediatric treatment standard â†’ AATD prevented entirely â†’ disease eliminated

**"We don't just wait for the cure. We make it happen."**

---

**Support Gene Therapy Research & Access**

**Mark Egly Foundation Gene Therapy Program**
ğŸ“§ Email: genetherapy@markeglyfoundation.org
ğŸ’Š Clinical Trials: trials@markeglyfoundation.org
ğŸ’° Donate: MarkEglyFoundation.org/GenTherapy

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"The cure is coming. Let's make sure every patient can access it."_

**â€” Mark Egly Foundation**
